Drug Trial Radar · NCT02041195
Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients
Last checked: Nov 20, 2026Latest source record: Aug 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
99
Actual
Start
Jan 2014
Primary completion
Aug 2014
Study completion Dec 2014
Sponsor
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 20, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effects of a new daily subcutaneous (SC) injectable formulation of setmelanotide (RM-493) in healthy participants with obesity on mean percent body weight loss and other weight loss parameters, as well as pharmacokinetic (PK) profile. The study is designed to evaluate the efficacy and tolerability of setmelanotide administered once or twice daily. The study drug (setmelanotide and placebo) will be administered in a blinded fashion.
Conditions
- Overweight and Obesity
Interventions
SetmelanotideDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Body Weight - Stage ATime frame: Baseline
- Percent Change From Baseline in Body Weight at Week 12 - Stage ATime frame: Baseline, Week 12
- Body Weight - Stage BTime frame: Baseline
- Percent Change From Baseline in Body Weight at Week 12 - Stage BTime frame: Baseline, Week 12
- Body Weight - Stage CTime frame: Baseline
- Percent Change From Baseline in Body Weight at Week 12 - Stage CTime frame: Baseline, Week 12
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) - Stage ATime frame: From first dose up to Day 114
- Number of Participants With TEAEs - Stage BTime frame: From first dose up to Day 114
- Number of Participants With TEAEs - Stage CTime frame: From first dose up to Day 114
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Dallas, Texas
Site not named
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.